Amarin Corp Plc (AMRN)

[Whalatane]

ICER report for Repatha

https://icer-review.org/announcements/icer-publishes-final-new-evidence-update-for-alirocumab-a-pcsk9-inhibitor-for-treating-high-cholesterol/

Note
–Based on new analyses of published results of the ODYSSEY Outcomes trial, alirocumab would meet cost-effectiveness thresholds if priced between $2,300 and $4,000 per year, depending on population–

in more detail

Based on these new analyses, ICER is revising its value-based price benchmark ranges for alirocumab to $2,300-$3,500 per year if used to treat all patients who meet ODYSSEY trial eligibility criteria

Vascepa is going to beat this by a mile IMHO especially for the R-IT diabetic population

Kiwi